Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03276468
Recruitment Status : Active, not recruiting
First Posted : September 8, 2017
Last Update Posted : December 7, 2021
Information provided by (Responsible Party):
The Lymphoma Academic Research Organisation

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : September 19, 2019
Estimated Study Completion Date : August 22, 2022